RxDoctor Payments Data

Jameel Shahzada, MD

Family Medicine · Modesto, CANPI 1790033678

Payments from drug & device makers

$496in general payments, 2019–2025

Across 31 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$117
  • GSK$77
  • Lilly USA, LLC$63
  • Pfizer$55
  • Boehringer Ingelheim$42
  • AMAG Pharmaceuticals, Inc.$24
  • plus $117 from 8 others

What the payments were for

  • Food & beverage$47295%
  • Education$245%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$496 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$215,827
Medicare patients
486
Services billed
1,856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$75,431
EliquisApixaban49$68,524
JanuviaSitagliptin Phosphate24$23,729
EntrestoSacubitril/Valsartan12$19,423
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$14,787
LinzessLinaclotide23$14,122
GemtesaVibegron16$11,219
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen285$6,517
Atorvastatin Calcium536$5,420
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$4,764
Breo ElliptaFluticasone/Vilanterol11$4,346
PaxlovidNirmatrelvir/Ritonavir15$4,288
Gabapentin128$3,214
Qvar RedihalerBeclomethasone Dipropionate15$3,059
Albuterol Sulfate HfaAlbuterol Sulfate77$2,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$117$75,43155 claims
PfizerEliquis, Paxlovid$55$72,81264 claims
MerckJanuvia$14$23,72924 claims
NovartisEntresto$11$19,42312 claims
GSKBreo Ellipta$77$4,34611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →